Great news around technology developed at UHN!
UHN Start-up AVROBIO, Inc. Announces $60 Million Series B Financing to Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic Diseases | TDC
Company to initiate Phase 2 trial with lead gene therapy, AVR‑RD‑01, based on promising initial clinical data in Fabry disease Strong investor syndicate supports multi-product portfolio with three additional gene therapies for Gaucher disease, cystinosis and Pompe disease
Join in on the conversation with Allison Aab when you subscribe to Toronto Health.